Mark Shawn Frank Net Worth

The estimated Net Worth of Mark Shawn Frank is at least $190 Thousand dollars as of 23 May 2013. Mark Frank owns over 20,000 units of ProPhase Labs Inc stock worth over $189,527 and over the last 14 years Mark sold PRPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Frank PRPH stock SEC Form 4 insiders trading

Mark has made over 1 trades of the ProPhase Labs Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Mark bought 20,000 units of PRPH stock worth $33,000 on 23 May 2013.

The largest trade Mark's ever made was buying 20,000 units of ProPhase Labs Inc stock on 23 May 2013 worth over $33,000. On average, Mark trades about 2,000 units every 0 days since 2010. As of 23 May 2013 Mark still owns at least 70,195 units of ProPhase Labs Inc stock.

You can see the complete history of Mark Frank stock trades at the bottom of the page.

Insiders trading at ProPhase Labs Inc

Over the last 15 years, insiders at ProPhase Labs Inc have traded over $6,868,501 worth of ProPhase Labs Inc stock and bought 2,996,691 units worth $4,189,802 . The most active insiders traders include Braden Michael Leonard, Ted William Karkus, and James T Mccubbin. On average, ProPhase Labs Inc executives and independent directors trade stock every 98 days with the average trade being worth of $586,896. The most recent stock trade was executed by Ted William Karkus on 1 February 2023, trading 500,000 units of PRPH stock currently worth $300,000.

What does ProPhase Labs Inc do?

prophase labs is a diversified natural health medical science company. for more information visit us at www.prophaselabs.com.

Complete history of Mark Frank stock trades at ProPhase Labs Inc

ProPhase Labs Inc executives and stock owners

ProPhase Labs Inc executives and other stock owners filed with the SEC include:

• Ted William Karkus,
  Chairman & CEO
• Monica Brady,
  Chief Financial Officer
• Ted Karkus,
  Chairman of the Board, Chief Executive Officer
• Monica Brady,
  Chief Financial Officer
• Warren Hirsch,
  Independent Director
• Louis Gleckel,
  Independent Director
• Jason Barr,
  Independent Director
• Sergio Miralles,
  Exec. VP & Chief Information Officer of ProPhase Diagnostics
• Sam A. Beeler,
  Chief Strategy Officer of Precision Medicine
• Jason Karkus,
  Exec. VP & Co-COO
• Alice Lioi,
  Exec. VP & Co-COO
• Mark S Leventhal,
  Director
• Mark Shawn Frank,
  Director
• James T Mccubbin,
  Director
• Mark A. Burnett,
  Director
• Braden Michael Leonard,
  10% owner
• Guy J Quigley,
  10% owner
• Robert V Jr Cuddihy,
  Chief Operating Officer
• John De Shazo,
  Director
• Jed Latkin,
  Director
• Robert A. Jr. Morse,
  CHIEF FINANCIAL OFFICER